D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The company’s product pipeline focuses on a range of indications including neurodegenerative and fibrotic diseases as well as application of big data in CNS drug research and diagnostics. D&D Pharmatech is the parent company of U.S.-based Neuraly, Precision Molecular, Valted Seq and Theraly Fibrosis.
Therapeutic Focus
Building a global biotech company
D&D runs global product development operations via multiple partnerships and owns subsidiaries focused on specific therapeutic areas. D&D is a technology and financial holding company that operates at two research and development sites: Korea (Pangyo) and U.S. (Gaithersburg, MD).
D&D Pharmatech was founded in 2014 in Korea and expanded to the U.S. through research and development collaborations with multiple scientific co-founders from academia and industry.
Seulki Lee, PhD
Founder, Chairman, Chief Executive Officer, D&D Pharmatech
Viktor Roschke, PhD
Chief Scientific Officer, D&D Pharmatech, Neuraly and Theraly Fibrosis
Sungmook Lim, PhD
Founder, Co-Chief Executive Officer, D&D Pharmatech
Sunghoon Hong, KICPA
Chief Financial Officer, D&D Pharmatech
Martin G. Pomper, MD, PhD
Founder and interim Chief Scientific Officer, Precision Molecular
Valina L. Dawson, PhD
Founder and Chief Executive Officer, Valted Seq
Ted M. Dawson, MD, PhD
Founder and Chief Scientific Officer, Valted Seq
Kang Choon Lee, PhD
Founder, D&D Pharmatech
Adam Bell, PhD
Vice President Regulatory Affairs Neuraly
Barbara Rempe, SHRM-CP
Human Resource Manager Neuraly
Celia Baula, PMP, MBA
Director
R&D Program Management Neuraly
Daniel Lee, MS
Executive Director
Clinical Affairs
Neuraly
Don Ho, PhD
Director
Intellectual Property Neuraly
Dong Ik Lee, PhD
Principal Scientist Drug Discovery Neuraly
Gil Price, MD
Clinical Safety Officer
Neuraly
Isabell Loftin, PhD
Vice President
Diagnostics
Valted Seq
JinSik Kim, CPA
Director
Accounting and Finance
D&D Pharmatech
Joshua Yang, MS
Head
Business Development
D&D Pharmatech
Mohammad N Ranjbar, PhD
Director
Bioinformatics
Valted Seq
Nayoung Louie, PhD
Director
Strategy
Neuraly
Nina Urban, MS, MBA
Vice President
Alliance Management
Neuraly
Okcheol Jeon, PhD
Principal Scientist
Drug Discovery
D&D Pharmatech
Pankaj J.
Pasricha, MD
Clinical Advisor
P4 Microbiome
Philip Phan, PhD
Strategic Advisor
P4 Microbiome
Pyung Ah Park
Internal Auditor/Legal Counsel
D&D Pharmatech
Sheri Fan, CPA
Director
Accounting and Finance
Neuraly
Svetlana Sosnovtseva, MS
Senior Director
Assay Development
Neuraly
Yen Lin, PhD
Executive Director
CMC
Neuraly
D&D’s commitment to science and cutting-edge research is reflected in our track record of publications. A few recent examples of high impact and high-quality publications co-authored by D&D scientific co-founders and scientists related to our products.
JAN 08, 2021
Neuraly Announces Strategic SRA with the University of Pennsylvania to Explore use of NLY01
https://www.businesswire.com/news/home/20201110005067/en/Neuraly-Announces-Strategic-Sponsored-Resea
DEC 17, 2020
DEC 10, 2020
Five Johns Hopkins faculty named to National Academy of Inventors
https://hub.jhu.edu/2020/12/08/national-academy-of-inventors/
NOV 02, 2020
NOV 02, 2020
Receiving FDA Clearance of IND Application to Initiate Phase 2B Trial of NLY01 for Patients with AD
https://www.businesswire.com/news/home/20201102005054/en/Neuraly-Receives-FDA-Clearance-of-Investiga
D&D Pharmatech (Korea)
5th Floor, I&C Building, 24, Pangyo-ro 255 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, (13486) Rep. of Korea
Tel : +82-31-8019-7771
Fax : +82-31-8019-7772
E-mail : info@ddpharmatech.com
D&D Pharmatech / Neuraly, Inc (US)
704 Quince Orchard Road, Suite 320
Gaithersburg, MD 20878
E-mail : info@neuralymed.com